tetano
Editor, Senior Moderator
Chem Commun (Camb)
. 2022 Jan 18.
doi: 10.1039/d1cc06520c. Online ahead of print.
RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern
Shi-Hao Zhou[SUP] 1 [/SUP], Ru-Yan Zhang[SUP] 1 [/SUP], Hai-Wei Zhang[SUP] 2 [/SUP], Yan-Ling Liu[SUP] 1 [/SUP], Yu Wen[SUP] 1 [/SUP], Jian Wang[SUP] 1 [/SUP], Yu-Ting Li[SUP] 1 [/SUP], Zi-Wei You[SUP] 1 [/SUP], Xu-Guang Yin[SUP] 1 [/SUP], Hong Qiu[SUP] 3 [/SUP], Rui Gong[SUP] 2 [/SUP], Guang-Fu Yang[SUP] 1 [/SUP], Jun Guo[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus 2019 (COVID-19) pandemic is causing serious impacts in the world, and safe and effective vaccines and medicines are the best methods to combat the disease. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a key role in interacting with the angiotensin-converting enzyme 2 (ACE2) receptor, and is regarded as an important target of vaccines. Herein, we constructed the adjuvant-protein conjugate Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]-RBD as a vaccine candidate, in which the N-terminal of the RBD was site-selectively oxidized by transamination and conjugated with the TLR1/2 agonist Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]. This demonstrated that the conjugation of Pam[SUB]3[/SUB]CSK[SUB]4[/SUB] significantly enhanced the anti-RBD antibody response and cellular response. In addition, sera from the Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]-RBD immunized group efficiently inhibited the binding of the RBD to ACE2 and protected cells from SARS-CoV-2 and four variants of concern (alpha, beta, gamma and delta), indicating that this adjuvant strategy could be one of the effective means for protein vaccine development.
. 2022 Jan 18.
doi: 10.1039/d1cc06520c. Online ahead of print.
RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern
Shi-Hao Zhou[SUP] 1 [/SUP], Ru-Yan Zhang[SUP] 1 [/SUP], Hai-Wei Zhang[SUP] 2 [/SUP], Yan-Ling Liu[SUP] 1 [/SUP], Yu Wen[SUP] 1 [/SUP], Jian Wang[SUP] 1 [/SUP], Yu-Ting Li[SUP] 1 [/SUP], Zi-Wei You[SUP] 1 [/SUP], Xu-Guang Yin[SUP] 1 [/SUP], Hong Qiu[SUP] 3 [/SUP], Rui Gong[SUP] 2 [/SUP], Guang-Fu Yang[SUP] 1 [/SUP], Jun Guo[SUP] 1 [/SUP]
Affiliations
- PMID: 35040862
- DOI: 10.1039/d1cc06520c
Abstract
The coronavirus 2019 (COVID-19) pandemic is causing serious impacts in the world, and safe and effective vaccines and medicines are the best methods to combat the disease. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a key role in interacting with the angiotensin-converting enzyme 2 (ACE2) receptor, and is regarded as an important target of vaccines. Herein, we constructed the adjuvant-protein conjugate Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]-RBD as a vaccine candidate, in which the N-terminal of the RBD was site-selectively oxidized by transamination and conjugated with the TLR1/2 agonist Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]. This demonstrated that the conjugation of Pam[SUB]3[/SUB]CSK[SUB]4[/SUB] significantly enhanced the anti-RBD antibody response and cellular response. In addition, sera from the Pam[SUB]3[/SUB]CSK[SUB]4[/SUB]-RBD immunized group efficiently inhibited the binding of the RBD to ACE2 and protected cells from SARS-CoV-2 and four variants of concern (alpha, beta, gamma and delta), indicating that this adjuvant strategy could be one of the effective means for protein vaccine development.